bright ideas
made brilliant

We take current therapies and make them better.

at Propella

We advance promising therapies with high efficiency and reduced risk due to the fact that all of our product candidates are developed using proven active ingredients. Our new and patented best-in-class products appeal to both patients and physicians.

Every day we are earnestly pushing ahead.

our approach

We start with good, and rapidly and intelligently move to great.
> learn more

our pipeline

Discover the potential that is currently underway at Propella
> learn more

latest news

Propella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.

Propella Therapeutics, Inc. presented "A Phase 1/2a, Open-label, Multicenter Study of Intramuscular Abiraterone Decanoate (PRL-02) Depot in Patients with Advanced Prostate Cancer (NCT04729114)" at the American Society of Clinical Oncology Annual Meeting on June 4, 2021.

Propella Therapeutics, Inc., a biopharmaceutical company focused on developing innovative, best-in-class oncology drugs, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PRL-02 (abiraterone decanoate), a potentially best-in-class therapy for metastatic prostate cancer. Propella also announced the appointment of Brendan Griffin to its leadership team as Chief Financial Officer.

“Propella” comes from the combination of “propel”, to drive, push and cause forward or upward motion, and “Capella”, a first magnitude star used in navigation. Capella consists of a primary pair of stars, which enhance, illuminate and strengthen each other, ultimately appearing as one.

Investing

bright ideas made brilliant

at Propella

our approach

our pipeline

latest news

bright ideas
made brilliant